Isobaric Tags for Relative and Absolute Quantitation in Proteomic Analysis of Potential Biomarkers in Invasive Cancer, Ductal Carcinoma In Situ, and Mammary Fibroadenoma

Hao Wu; Hao Wu; Hao Wu; Hao Wu; Hao Wu; Xian-Yu Zhang; Xian-Yu Zhang; Xian-Yu Zhang; Ming Niu; Ming Niu; Ming Niu; Fei-Feng Li; Fei-Feng Li; Fei-Feng Li; Song Gao; Song Gao; Song Gao; Wei Wei; Wei Wei; Wei Wei; Si-Wei Li; Si-Wei Li; Si-Wei Li; Xing-Da Zhang; Xing-Da Zhang; Xing-Da Zhang; Shu-Lin Liu; Shu-Lin Liu; Shu-Lin Liu; Shu-Lin Liu; Da Pang; Da Pang; Da Pang; Da Pang; Da Pang

doi:10.3389/fonc.2020.574552

Frontiers in Oncology (Oct 2020)

Isobaric Tags for Relative and Absolute Quantitation in Proteomic Analysis of Potential Biomarkers in Invasive Cancer, Ductal Carcinoma In Situ, and Mammary Fibroadenoma

Hao Wu,
Hao Wu,
Hao Wu,
Hao Wu,
Hao Wu,
Xian-Yu Zhang,
Xian-Yu Zhang,
Xian-Yu Zhang,
Ming Niu,
Ming Niu,
Ming Niu,
Fei-Feng Li,
Fei-Feng Li,
Fei-Feng Li,
Song Gao,
Song Gao,
Song Gao,
Wei Wei,
Wei Wei,
Wei Wei,
Si-Wei Li,
Si-Wei Li,
Si-Wei Li,
Xing-Da Zhang,
Xing-Da Zhang,
Xing-Da Zhang,
Shu-Lin Liu,
Shu-Lin Liu,
Shu-Lin Liu,
Shu-Lin Liu,
Da Pang,
Da Pang,
Da Pang,
Da Pang,
Da Pang

Affiliations

Hao Wu: Genomics Research Center, College of Pharmacy, State-Province Laboratory of Biomedicine and Pharmaceutics of China, Harbin Medical University, Harbin, China
Hao Wu: Sino-Russian Medical Research Center, Harbin Medical University Cancer Hospital, Harbin, China
Hao Wu: Heilongjiang Academy of Medical Sciences, Harbin Medical University, Harbin, China
Hao Wu: HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
Hao Wu: Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
Xian-Yu Zhang: Genomics Research Center, College of Pharmacy, State-Province Laboratory of Biomedicine and Pharmaceutics of China, Harbin Medical University, Harbin, China
Xian-Yu Zhang: Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
Xian-Yu Zhang: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
Ming Niu: Genomics Research Center, College of Pharmacy, State-Province Laboratory of Biomedicine and Pharmaceutics of China, Harbin Medical University, Harbin, China
Ming Niu: Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
Ming Niu: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
Fei-Feng Li: Genomics Research Center, College of Pharmacy, State-Province Laboratory of Biomedicine and Pharmaceutics of China, Harbin Medical University, Harbin, China
Fei-Feng Li: HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
Fei-Feng Li: Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
Song Gao: Genomics Research Center, College of Pharmacy, State-Province Laboratory of Biomedicine and Pharmaceutics of China, Harbin Medical University, Harbin, China
Song Gao: Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
Song Gao: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
Wei Wei: Genomics Research Center, College of Pharmacy, State-Province Laboratory of Biomedicine and Pharmaceutics of China, Harbin Medical University, Harbin, China
Wei Wei: Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
Wei Wei: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
Si-Wei Li: Genomics Research Center, College of Pharmacy, State-Province Laboratory of Biomedicine and Pharmaceutics of China, Harbin Medical University, Harbin, China
Si-Wei Li: Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
Si-Wei Li: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
Xing-Da Zhang: Genomics Research Center, College of Pharmacy, State-Province Laboratory of Biomedicine and Pharmaceutics of China, Harbin Medical University, Harbin, China
Xing-Da Zhang: Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
Xing-Da Zhang: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
Shu-Lin Liu: Genomics Research Center, College of Pharmacy, State-Province Laboratory of Biomedicine and Pharmaceutics of China, Harbin Medical University, Harbin, China
Shu-Lin Liu: HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
Shu-Lin Liu: Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
Shu-Lin Liu: Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada
Da Pang: Genomics Research Center, College of Pharmacy, State-Province Laboratory of Biomedicine and Pharmaceutics of China, Harbin Medical University, Harbin, China
Da Pang: Sino-Russian Medical Research Center, Harbin Medical University Cancer Hospital, Harbin, China
Da Pang: Heilongjiang Academy of Medical Sciences, Harbin Medical University, Harbin, China
Da Pang: Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
Da Pang: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China

DOI: https://doi.org/10.3389/fonc.2020.574552
Journal volume & issue: Vol. 10

Abstract

Read online

ObjectivesBreast malignancy is a serious threat to women’s health around the world. Following the rapid progress in the field of cancer diagnostics and identification of pathological markers, breast tumor treatment methods have been greatly improved. However, for invasive, ductal carcinomas and mammary fibroadenoma, there is an urgent demand for better breast tumor-linked biomarkers. The current study was designed to identify diagnostic and/or therapeutic protein biomarkers for breast tumors.MethodsA total of 140 individuals were included, comprising 35 healthy women, 35 invasive breast cancers (IBC), 35 breast ductal carcinomas in situ (DCIS), and 35 breast fibroadenoma patients. Isobaric tags for relative and absolute quantitation (iTRAQ) proteomic analysis was employed to characterize differentially expressed proteins for potential biomarkers in IBC, DCIS, and fibroadenomas by comparisons with their matched adjacent tissues and/or normal breast tissues. The public databases Metascape and String were used for bioinformatic analyses.ResultsUsing the proteomics approach, we identified differentially expressed proteins in tissues of different breast tumors compared to normal/adjacent breast tissues, including 100 in IBC, 52 in DCIS, and 44 in fibroadenoma. Among the 100 IBC differentially expressed proteins, 37 were found to be specific to this type of cancer only. Additionally, four proteins were specifically expressed in DCIS and four in fibroadenoma. Compared to corresponding adjacent tissues and normal breast tissues, 18 step-changing proteins were differentially expressed in IBC, 14 in DCIS, and 13 in fibroadenoma, respectively. Compared to DCIS and normal breast tissues, 65 proteins were differentially expressed in IBC with growing levels of malignancy.ConclusionsThe identified potential protein biomarkers may be used as diagnostic and/or therapeutic targets in breast tumors.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords